Sodium Alginate for LPR | Natural Support for Silent Reflux

Last updated: October 1, 2026

Sodium Alginate For LPR

Sodium alginate has been used for reflux for decades, but its role in LPR is getting new attention. First, what exactly is LPR? Most people have experienced acid reflux before. Eating a pizza with a beer is enough to trigger those uncomfortable symptoms of chest pain, heartburn, and nausea. While these symptoms point to gastroesophageal reflux disease (GERD), some people with reflux never get heartburn at all. In this case, we call it silent reflux. Laryngopharyngeal reflux (LPR), also known as silent reflux, respiratory reflux, or extra-esophageal reflux, usually doesn't cause heartburn. Instead, it causes throat and voice symptoms. Simply, the contents of your stomach go up the esophagus, then find their way to your throat, nasal passages, and voice box. In medicine, we refer to these structures as the larynx and pharynx, hence the name laryngopharyngeal reflux.

The unusual thing about LPR is that you may not connect your symptoms to reflux at all, because heartburn is often missing. One review found that only about 35% of LPR patients report heartburn (Franco, 2006). From a prevalence point of view, GERD is extremely common. According to the NIH, GERD affects about 20% of Americans. The exact prevalence of LPR is unknown, but studies using symptom questionnaires estimate that LPR-related symptoms affect 5 to 30% of people (Lechien et al., 2020). LPR can be both underdiagnosed and overdiagnosed: many people don't realize that chronic cough, hoarseness, or throat clearing can be related to reflux, while other conditions such as allergies, postnasal drip, and voice strain can mimic LPR.

In this article, we will cover laryngopharyngeal reflux, how it is evaluated, current approaches to managing it, and the research on long-term proton pump inhibitor use.

What are the signs and symptoms of LPR?

As just mentioned, LPR patients may not experience the classic reflux symptoms of GERD. In some cases, the symptoms of LPR may be confused for GERD, and vice versa. Sometimes GERD is confused for a heart attack.

With that said, LPR has a unique clinical presentation, which includes:

• Chronic cough
• Sore throat
• Vocal hoarseness (i.e, dysphonia)
• Difficulty swallowing (i.e., dysphagia)
• Swollen and sore larynx aka “voice box”
• Chronic clearing of the throat
• Feeling thick mucus at the back of the throat

These symptoms are not specific to LPR. The 2025 San Diego Consensus, a joint guideline from gastroenterology and otolaryngology experts, emphasizes that throat symptoms alone do not confirm reflux, and that causes such as allergies, sinus disease, and voice overuse should be considered (Yadlapati et al., 2025).

LPR vs. GERD – Similarities and Differences

Feature	GERD	LPR (Silent Reflux)
Typical symptoms	Heartburn, chest pain, nausea	Chronic cough, hoarseness, throat clearing, mucus
Heartburn present?	Usually	Often absent ("silent")
Main damaging agent	Acid	Pepsin (stable at higher pH and reactivated by acid)
Tissue affected	Esophagus (more resilient)	Larynx / pharynx (more delicate)
Responds to PPIs?	Generally yes	Often poorly, especially weakly acidic or alkaline reflux

An abnormally relaxed lower esophageal sphincter (LES) can lead to the regurgitation of your stomach content to the esophagus. The function of the LES is to keep gastric content in the stomach. When it doesn’t work properly, reflux develops. While LPR and GERD are quite different from one another, they have a few similarities. For instance, both conditions may affect otherwise healthy individuals.

They also share the same risk factors, including:

• Obesity
• Smoking
• Excessive drinking of alcohol
• Binge-eating
• Pregnancy

Moreover, you can have LPR and GERD at the same time. Some healthcare professionals consider LPR part of the GERD spectrum, while others find it useful to treat the two conditions separately. Still, LPR and GERD do not always occur together. Some patients have GERD without LPR and vice versa. The lining of the larynx is more delicate than that of the esophagus and can be irritated by fewer reflux episodes, so throat symptoms can appear even when reflux events are infrequent.

Researchers have found a connection between pepsin in the throat and airways and LPR. This enzyme breaks down protein and is considered one of the main irritants in LPR. Pepsin is most active in acidic conditions, but it remains stable at higher pH and can be reactivated when acid returns. Researchers believe that pepsin may reach the throat in liquid and possibly aerosolized form, adhere to the throat lining, and become reactivated when acid reflux or acidic food or drink contacts it. Activated pepsin can break down proteins in the mucous membranes of the throat, contributing to the inflammation and irritation of LPR.

How to diagnose LPR and GERD

The diagnosis of LPR and GERD follows the usual routine of medicine:

Taking your medical history

Your doctor will ask you about the symptoms you’ve been experiencing. He/she will also ask about your symptoms duration, dietary habits, triggering factors, and relieving factors. The information gathered at this step is the most important to make an accurate diagnosis. Therefore, do your best to be transparent with your doctor.

Conducting a physical examination

A physical examination to diagnose LPR and GERD is typically normal. However, it could reveal complications of GERD, including pneumonia. In this case, your doctor will listen to your lungs using a stethoscope. An ENT doctor may also look at your larynx with a small camera (laryngoscopy), although laryngoscopy findings alone cannot confirm LPR.

Ordering some follow-up tests

Follow-up tests are important to diagnose both conditions. However, they are not always necessary. Tests become important when symptoms persist, when throat symptoms occur without heartburn or regurgitation, or when stronger treatment is being considered. For example, Barrett’s esophagus is one key complication of GERD. Unfortunately, it is a precancerous state. In other words, if not monitored and managed, it may develop into esophageal cancer. To assess the esophagus, your doctor may order an upper endoscopy.

Another test that your doctor may order is ambulatory reflux monitoring, such as 24-hour pH-impedance testing or 96-hour wireless pH monitoring. These tests use a thin probe or a small capsule placed in the esophagus.

Reflux monitoring provides the following data:

• The frequency of reflux episodes (i.e., when stomach contents flow back into the esophagus)
• How acidic each reflux episode is (pH-impedance also detects weakly acidic and non-acid reflux)
• How long the refluxate remains in your esophagus

If LPR is suspected, you may need to see a specialist. The expert in this field is an otolaryngologist, colloquially known as an ear, nose, and throat (ENT) doctor. Historically, the standard approach for suspected LPR has been an empiric trial of a PPI. The 2025 San Diego Consensus refines this: when throat symptoms occur together with heartburn or regurgitation, lifestyle changes and an empiric trial of acid suppression with or without alginates are appropriate, while upper endoscopy and reflux monitoring are recommended when throat symptoms are isolated, persist, or require escalation of treatment (Yadlapati et al., 2025).

What the research says about long-term PPI use

Proton pump inhibitors (PPIs) are drugs that interfere with the release of acid in the stomach. This increases the pH of stomach content (makes it less acidic), which lowers the risk of having symptoms. Common PPIs include omeprazole (Prilosec), lansoprazole (Prevacid), dexlansoprazole (Dexilant), esomeprazole (Nexium), and pantoprazole (Protonix). Before PPIs, options for acid-related disorders were limited to antacids, H2 blockers, and, for severe or complicated disease, surgery. When PPIs became available, they were a major advance.

For many years, PPIs were considered safe and well-tolerated. However, a growing body of research has linked long-term use to several health concerns. Most of this research is observational, which means it shows associations rather than proof that PPIs cause these problems. Even so, it is a reason to use PPIs only when they are clearly needed, at the lowest effective dose.

PPIs and C. difficile infection

Mayo Clinic researchers reported that long-term PPI use is associated with reduced diversity of the gut microbiome, which may increase the risk of infections and other complications. The bacteria in your gut have many roles, including the digestion of food and production of certain nutrients.

A 2017 meta-analysis of 56 studies with more than 356,000 patients found that PPI use was associated with roughly double the odds of Clostridioides difficile (formerly Clostridium difficile) infection. The authors noted that further high-quality studies are needed to confirm whether the link is causal.

Symptoms of C. difficile infection include:

• Dehydration
• Fever
• Nausea
• Watery diarrhea
• Abdominal cramping
• Tachycardia (i.e., rapid heart rate)
• Increased white blood cell count
• Kidney failure

PPIs and magnesium deficiency

The United States Food and Drug Administration (FDA) released a drug safety communication on March 2, 2011, warning that long-term use of prescription PPIs can lower magnesium (Mg) levels. Low magnesium can affect:

• Cardiac function
• Muscle contraction and relaxation
• Electrical heart rhythms
• Brain signaling pathways

According to the FDA, in about a quarter of the cases it reviewed, magnesium supplementation alone did not correct the deficiency and the PPI had to be stopped. For transparency’s sake, the FDA noted that these risks are more likely with prescription PPIs, because over-the-counter (OTC) PPIs usually come in lower doses. Over-the-counter PPIs are labeled for a 14-day course of treatment, no more than three times a year, unless a doctor advises otherwise.

PPIs and community-acquired pneumonia

A 2018 study analyzed the risk of community-acquired pneumonia with long-term PPI use. It included more than 75,000 adults aged 60 and older who were prescribed PPIs for one year or longer, compared with matched controls. During the second year of treatment, PPI use was associated with a significantly higher risk of pneumonia, after accounting for pneumonia rates before treatment began.

The mechanism is not fully understood. Researchers think that PPIs reduce the stomach's acid barrier, allowing bacteria that usually wouldn’t survive in an acidic environment to grow and reach the lungs via aspiration.

PPIs and dementia

Several studies have reported an association between PPI use and dementia, primarily in older adults. One large German study followed older adults over several years and found that regular PPI users had a 44% higher risk of developing dementia than non-users. The PPIs in question were omeprazole (Prilosec), pantoprazole (Protonix), and esomeprazole (Nexium). The researchers suggested that avoiding unnecessary PPI use may help prevent dementia, a hypothesis that is consistent with mouse studies in which PPIs increased β-amyloid levels in the brain. Other studies have not found the same association, so this remains an area of active research.

PPIs and the risk of kidney disease

Shortly after the introduction of PPIs, case reports emerged suggesting an association between PPI use and kidney injury, specifically acute interstitial nephritis (AIN). The first large-scale study examining the relationship between PPI use and chronic kidney disease (CKD) included two patient cohorts intended to represent the general population. In each, PPI use was associated with a higher risk of developing CKD. A 2016 study of U.S. veterans found that PPI use was associated with a higher incidence of CKD, kidney disease progression, and end-stage renal disease (ESRD). The mechanism behind this association is not well understood. One hypothesis is that AIN caused by PPI use can lead to CKD.

Summary of the current research on PPIs

We have touched on just some of the risks associated with PPI use. The American Gastroenterological Association (AGA) reviewed the risks and benefits of long-term PPI therapy in 2017. Its review discussed several conditions that have been associated with PPI use, including acute kidney injury and chronic kidney disease, dementia, bone fractures, myocardial infarction, small intestinal bacterial overgrowth (SIBO), spontaneous bacterial peritonitis, Clostridium difficile infection, pneumonia, micronutrient deficiencies, and gastrointestinal malignancies. The AGA noted that the quality of evidence for most of these associations is low, and advised that patients with a clear indication should continue PPIs at the lowest effective dose, while patients without a clear indication should try to reduce or stop them. A 2019 literature review reported an association between long-term PPI use and gastric cancer risk. Two large studies in 2023 reported a higher dementia risk with prolonged PPI use (more than 4.4 years) in one, and an increasing rate ratio with longer use in the other. Finally, FDA-required prescribing information for PPIs includes warnings about possible effects such as acute interstitial nephritis, vitamin B12 deficiency, and hypomagnesemia.

Why are PPIs not always the best option for LPR?

Conventionally, doctors manage LPR / respiratory reflux with PPIs or sometimes H2 blockers to relieve persistent throat symptoms. The logic is lowering the acidity of the stomach to minimize throat irritation. While this approach helps some people, the evidence that PPIs improve throat symptoms is weak, and the long-term associations described above are a reason to avoid indefinite use without a clear indication.

One study, the TOPPITS trial, tested lansoprazole for persistent throat symptoms. This study recruited 346 participants in eight UK ENT departments.

The authors of the study divided participants into two groups:

The first group – They took lansoprazole.

The second group – They took an identical-looking pill without any effects (a placebo).

Neither the participants nor the researchers knew who was taking the real pill. Participants took the pill twice a day for 16 weeks.

Both groups improved by similar amounts, and participants on lansoprazole did not report better outcomes than those on placebo on any of the three symptom questionnaires used. The authors concluded that there was no evidence of benefit from treating persistent throat symptoms with lansoprazole.

Also, Lechien and colleagues report that weakly acidic and alkaline LPR are more prevalent than previously presumed and may concern more than 50% of patients. In their view, these patients may respond poorly to PPI therapy and need alginate therapy to address the non-acid component of reflux.

How alginate therapy works

Alginate is an anionic polysaccharide occurring naturally in brown seaweed, aka kelp. When alginate and bicarbonate contact stomach acid, they form a low-density gel raft that floats on top of the stomach contents and can last up to four hours. This raft acts as a physical barrier at the top of the stomach that helps keep acid, pepsin, and other stomach contents from refluxing upward. Laboratory research suggests alginate rafts can also hold back pepsin and bile acids (Strugala et al., 2009).

Unlike PPIs, which take days to reach full effect, an alginate-bicarbonate preparation begins forming its raft within minutes of reaching the stomach. Alginate therapy is also non-systemic. This means it works by forming a physical barrier at the top of the stomach, and its effect is limited to that location. By contrast, cutting off acid production with PPIs has been associated with effects on multiple body systems with long-term use.

Alginates have been well studied for reflux. A 2017 meta-analysis of 14 randomized trials in GERD found that alginates were significantly more effective than placebo or antacids for symptom relief; compared with PPIs or H2 blockers, alginates appeared somewhat less effective, though the difference was not statistically significant. LPR-specific evidence is newer and is discussed below. Alginates are generally well tolerated. Because sodium alginate is a soluble fiber, high intakes can cause mild bloating, looser stools, or constipation; these effects are uncommon at Refluxter's labeled dose of up to 8 capsules per day. Many physicians in the U.S. are not yet familiar with alginate therapy for LPR, even though alginates for reflux have been used in Europe since the 1970s.

Sodium alginate vs. magnesium alginate for LPR

Alginate reflux products use different salts of alginic acid, most commonly sodium alginate or magnesium alginate. Both are derived from brown seaweed, and both form the same type of protective gel raft when they react with stomach acid, so the mechanism is the same. The clinical evidence in LPR includes both forms. A 2009 UK pilot study used a liquid sodium alginate suspension (Gaviscon Advance®), while two Italian studies discussed below used a magnesium alginate suspension (Gastrotuss®).

Most recently, a 2025 systematic review published in the European Archives of Oto-Rhino-Laryngology screened 134 articles and included 16 studies of alginate therapy for LPR. It concluded that alginates demonstrate a beneficial role both as a stand-alone treatment and in combination with PPIs, and called for larger randomized studies. Importantly, the review evaluates alginates as a class, and what matters is that the product forms an effective raft. On the question of formulation, a 2019 review of alginate therapy identified sodium alginate, sodium bicarbonate, and calcium carbonate as the three active ingredients of the most effective alginate products, because together they form a strong, buoyant raft in the acidic stomach. Refluxter is built on this same three-ingredient combination.

Why is Nutritist’s Refluxter the best alginate for LPR?

Refluxter was formulated by an M.D.

A review on the role of pepsin in reflux stated that PPIs do not help the majority of people whose reflux symptoms arise beyond the esophagus, suggesting that acid may not be the main damaging agent there. Instead, pepsin plays a central role. Pepsin is an enzyme made in the stomach, and its presence in the larynx, in saliva, and in the breath of people with airway and lung disease suggests that reflux has played a part. Pepsin was once thought to become permanently inactive at pH 4 and above, so PPIs were expected to neutralize refluxed pepsin by raising gastric pH. However, research shows that pepsin is stable up to pH 7 and can be reactivated when acid returns. Pepsin can also be taken up into throat cells by endocytosis ('cellular swallowing') and cause damage from within. Based on these findings, it seems unlikely that acid suppression with PPIs alone will give people with LPR results comparable to those with typical acid reflux. The same review noted that specifically formulated alginates, which hold back pepsin, give benefit.

A 2009 randomized study found that a sodium alginate and bicarbonate suspension (Gaviscon Advance®) given to people with LPR significantly improved symptoms and clinical findings compared with a control group given no treatment, at the 2-month and 6-month assessments. A 2021 observational study without a control group enrolled 100 outpatients with LPR and gave them magnesium alginate for two months. Patients were assessed at baseline and at 15, 30, and 60 days. A visual analog scale assessed the perception of dysphonia, dysphagia, and cough, and all three improved significantly (p<0.0001). A 2022 randomized controlled trial enrolled 50 patients with LPR and split them into two groups of 25. It compared a magnesium alginate suspension (Gastrotuss®) with the PPI omeprazole. After 2 months, LPR symptoms and signs were significantly reduced in both groups, and the researchers concluded that alginate was non-inferior to PPI and may represent an alternative to PPIs for LPR.

Expert recommendations increasingly include alginates. A 2020 review by the LPR Study Group of the Young Otolaryngologists of IFOS proposed initial treatment combining dietary measures, PPIs, alginate, and magaldrate for three months, then adapting treatment to each patient's reflux profile. The 2025 San Diego Consensus also lists alginates as part of empiric treatment when throat symptoms occur with heartburn or regurgitation, and the 2025 systematic review discussed above found a beneficial role for alginates in LPR both as a stand-alone therapy and alongside PPIs. In the randomized LPR studies, outcomes were measured after two months of consistent use, with benefits maintained at six months in the 2009 study, when improvement in laryngeal examination findings also became significant. This is why we recommend taking Refluxter consistently for a full 8 weeks before deciding whether it is working for you.

Nutritist Refluxter is the best alginate supplement on the market today.

Because alginate products are sold in the form of supplements, there are no regulations that instruct manufacturers on how to develop these products. Many manufacturers use a random assortment of ingredients that are not equal or similar to the ingredients used in the clinical studies on sodium alginate therapy. Sometimes manufacturers include ingredients that you don’t want like polylysine, glycerine, aluminum, paraben, or 'natural flavor'. Other times they include sugars like dextrose or sugar substitutes like stevia, xylitol, or saccharin. Some manufacturers don't even include calcium carbonate and instead use calcium pantothenate, which was not an ingredient used in the clinical studies. In fact, calcium pantothenate is the calcium salt of Vitamin B5! Nutritist’s founder is an M.D. who studied clinical research papers such as the ones mentioned in this article and used the ingredients mentioned in the papers in their correct effective dosages when he created Refluxter. Indeed, a 2019 review of alginate therapy identified sodium alginate, sodium bicarbonate, and calcium carbonate as the three active ingredients of the most effective alginate products. We recommend that when looking at any alginate product, make sure it contains these three key ingredients with sodium alginate being the predominant, first ingredient listed.

Of importance, Refluxter has the most of the key ingredient sodium alginate in its formula compared to its competitors. By law manufacturers have to list ingredients in order of quantity present. According to FDA regulations, ingredients must be listed in descending order of predominance by weight. The first ingredient listed in Refluxter’s alginate complex is sodium alginate. The complex itself weighs 1,470 mg per serving, with over 1,000 mg derived from sodium alginate.

A competitor product lists calcium pantothenate as the first ingredient in its alginate complex, followed by sodium alginate. The complex itself weighs 425 mg per serving. Therefore, by FDA regulation sodium alginate cannot comprise more than 50% (212.5 mg) of the complex since it is the second ingredient listed. Another competitor product lists sodium alginate as the first ingredient in its alginate complex, but the complex itself only weighs 338 mg per serving. We estimate this product has around 240-300 mg of actual sodium alginate per serving. Therefore, Refluxter has an estimated 3.5x-5x the amount of sodium alginate per serving than present in these competitors! Many people report that taking the recommended serving of 5 ml of these competitor products is not enough to relieve their symptoms. Even if you were to double the dose to 10 ml, you still wouldn't get as much sodium alginate per serving compared to Refluxter. Refluxter also has no sugars or artificial sweeteners and isn't an inconvenient gel that needs to be measured, but a simple to swallow capsule. For these reasons, Refluxter is not only the best alginate for acid reflux support, but also the alginate one should reach for first when dealing with LPR symptoms. Also, Refluxter is the best value sodium alginate when one compares the actual sodium alginate present to the cost of the product (mg/$). That is, each product roughly costs $29 to $33, but ask yourself how much total sodium alginate is in the bottle and are you paying for mostly alginate or something else?

Why consider an alginate supplement like Refluxter?

First, throat symptoms related to reflux are often long-lasting, and many people want a daily option they can use over the long term. Long-term PPI or H2 blocker use without a clear indication is discouraged because of the associations described earlier.

Next, LPR often occurs without heartburn, so reflux can go unrecognized while throat symptoms continue. A non-systemic option that works locally in the stomach, without the systemic associations linked to long-term PPI use, is appealing for many people.

Lastly, research suggests that more than half of people with LPR may have weakly acidic or alkaline reflux, which acid suppression alone may not address. Because the alginate raft is a physical barrier, it helps hold back refluxate whether it is acidic or not.

Refluxter is designed to form a strong, protective raft after meals and at bedtime, supporting throat and esophageal comfort.^* Anyone with persistent throat symptoms should also see a doctor, since several other conditions can mimic LPR.

How to take Refluxter: Take 2 capsules after every meal and 2 capsules at bedtime, up to a maximum of 8 capsules per day. Consistency matters, and the bedtime dose is especially important because lying down makes it easier for stomach contents to travel upward. Be patient. The delicate tissue of the throat and voice box recovers slowly, and in the randomized alginate studies in LPR, results were measured after two months of consistent use, with benefits maintained at six months in the 2009 study (McGlashan et al., 2009, Eur Arch Otorhinolaryngol). For this reason, take Refluxter consistently after every meal and at bedtime for a full 8 weeks before judging whether it is working for you. Alginate is generally well tolerated; stay within the labeled maximum, and talk to your doctor about your calcium and sodium intake if you have kidney or blood pressure issues. We go over dosing schedules and other best practices when taking Refluxter in our "The Complete Refluxter Handbook" which can be downloaded for free here: https://go.nutritist.us/handbook

If you are ready to make the smart choice like many of our readers already have, check out Refluxter.

Takeaway message

LPR, or silent reflux, often occurs without heartburn, so it can be easy to miss. Its symptoms, such as hoarseness, chronic cough, and throat clearing, can overlap with many other conditions, which is why a proper evaluation matters. PPIs are commonly prescribed for LPR, but high-quality trials have not shown clear benefit for throat symptoms, and long-term use has been associated with a range of health concerns.

For people looking for a non-systemic way to support reflux and throat comfort, alginates are a well-studied option, and Refluxter is our recommendation.^* It uses basic chemistry to form a protective raft that helps keep acid and pepsin where they belong.

Sodium alginate has a long history of use for reflux and alginate-containing products are commonly recommended in pregnancy by healthcare professionals in many settings. However, because every pregnancy is unique and Refluxter is a dietary supplement, if you are pregnant we recommend discussing Refluxter with your obstetric provider before use.

We hope that this article managed to highlight the different aspects of LPR and how it is different from GERD.

Additional information is available on the Refluxter product page.

If you have any questions, concerns, or personal experiences with LPR, please do not hesitate to share your thoughts in the Comment section below. You can also use the Contact page to reach out for a private conversation.

Disclaimer: This article is not intended to provide medical advice. This article is intended for informational and educational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. This article does not constitute the formation of a patient-physician relationship. ^*The statements in this article have not been evaluated by the Food and Drug Administration. Refluxter is not intended to diagnose, treat, cure or prevent any disease. Please consult your physician for medical advice.

Frequently Asked Questions

What is sodium alginate?

Sodium alginate is a natural anionic polysaccharide extracted from brown seaweed (kelp). When combined with bicarbonate and exposed to stomach acid, it forms a low-density gel raft that floats on top of the stomach contents and acts as a physical barrier against reflux.

How does sodium alginate help with LPR (silent reflux)?

Sodium alginate forms a gel raft at the top of the stomach that helps hold back stomach contents, including acid and pepsin, so less reaches the throat and voice box. Because it is a physical barrier rather than an acid suppressant, the raft begins forming within minutes, and it is non-systemic, meaning its effect is limited to the stomach.

Is sodium alginate safe to use?

Alginates have been widely studied for reflux and are generally well tolerated, with minimal absorption into the body. If you have kidney or blood pressure concerns, monitor your calcium and sodium intake and consult your physician.

Does sodium alginate work for non-acidic or alkaline LPR?

Researchers estimate that more than half of people with LPR may have weakly acidic or alkaline reflux, which often responds poorly to PPIs. Because the alginate raft is a physical barrier, it helps hold back refluxate regardless of whether it is acidic or alkaline.

Sodium alginate vs. PPIs for LPR: which is better?

A randomized trial found magnesium alginate to be non-inferior to omeprazole for reducing LPR symptoms and signs after two months, and a large placebo-controlled trial found no benefit of lansoprazole for persistent throat symptoms. Current expert recommendations include alginates either with PPIs or as part of an empiric trial alongside lifestyle changes. Unlike PPIs, alginate is non-systemic, begins working within minutes, and avoids the long-term risks that have been associated with PPI use.

Is sodium alginate or magnesium alginate better for LPR?

Both are seaweed-derived alginate salts that form the same protective raft barrier, and clinical studies in LPR have shown benefits with both forms. A 2025 systematic review of 16 studies concluded that alginates as a class have a beneficial role in LPR. A 2019 review identified sodium alginate, sodium bicarbonate, and calcium carbonate as the three active ingredients of the most effective alginate products, the combination used in Refluxter.

How long does it take for Refluxter to work for LPR symptoms?

Throat symptoms tend to improve gradually, because the delicate tissue of the throat and voice box recovers slowly. In randomized studies of alginate therapy in LPR, results were measured after two months of consistent use, with benefits maintained at six months in one study (McGlashan et al., 2009). Take Refluxter consistently, 2 capsules after every meal and at bedtime (up to 8 capsules per day), and give it at least 8 weeks before judging how well it works for you. Stopping after a week or two is the most common reason people feel it 'did not work.'

How do you take Refluxter for LPR symptoms?

Take 2 capsules after every meal and 2 at bedtime, up to a maximum of 8 capsules per day, and try not to skip doses. The bedtime dose is especially important because lying down makes reflux easier. Because the throat recovers slowly, give Refluxter a consistent 8-week trial before assessing whether it works for you. Stay within the labeled maximum, and talk to your doctor about your calcium and sodium intake if you have kidney or blood pressure issues.

Further resources

• The San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease (2025)
• https://www.ncbi.nlm.nih.gov/books/NBK519548/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697179/
• https://pubmed.ncbi.nlm.nih.gov/16598989
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297018/
• https://pubmed.ncbi.nlm.nih.gov/12570026
• https://www.nature.com/gimo/contents/pt1/full/gimo46.html
• https://pubmed.ncbi.nlm.nih.gov/28375448/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836317/
• https://pubmed.ncbi.nlm.nih.gov/18506466/
• https://link.springer.com/article/10.1007/s00405-025-09693-2
• https://go.nutritist.us/handbook